Journal article
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer
Abstract
PURPOSE: ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC).
METHODS: One hundred seventy-one patients received intravenous pemetrexed 500 mg/m(2) day 1 and oral ABT-751 or placebo days 1 to 14 of 21-day …
Authors
Rudin CM; Mauer A; Smakal M; Juergens R; Spelda S; Wertheim M; Coates A; McKeegan E; Ansell P; Zhou X
Journal
Journal of Clinical Oncology, Vol. 29, No. 8, pp. 1075–1082
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 10, 2011
DOI
10.1200/jco.2010.32.5944
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCzech RepublicDisease-Free SurvivalDouble-Blind MethodFemaleGlutamatesGuanineHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPemetrexedProportional Hazards ModelsRisk AssessmentRisk FactorsSulfonamidesTime FactorsTreatment OutcomeUnited States